The 54 references in paper , статья Редакционная (2014) “Применение высоких доз N-ацетилцистеина у пациентов со стабильным течением хронической обструктивной болезни легких: двойное слепое рандомизированное плацебо-контролируемое исследование HIACE // High doses of N-acetylcysteine in patients with stable chronic obstructive pulmonary disease: results of 1-year randomized double-blind placebo-controlled HIACE study” / spz:neicon:pulmonology:y:2013:i:3:p:62-72

1
Evans M.D., Pryor W.A.Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am. J. Physiol. 1994; 266 (6, Pt 1): L593–L611.
(check this in PDF content)
2
Rahman I., MacNee W.Oxidative stress and regulation of glutathione in lung inflammation . Eur. Respir. J. 2000; 16 (3): 534–554. Оригинальные исследования
(check this in PDF content)
3
Sadowska A.M., Manuel,Y,Keenoy B., De Backer W.A. Antioxidant and anti-infl ammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo doseeffects: a review. Pulm. Pharmacol. Ther. 2007; 20 (1): 9–22.
(check this in PDF content)
4
Aruoma O.I., Halliwell B., Hoey B.M., Butler J.The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid . Free Radic. Biol. Med. 1989; 6 (6): 593–597.
(check this in PDF content)
5
Cotgreave I.A.N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv. Pharmacol. 1997; 38: 205–227.
(check this in PDF content)
6
Moldeus P., Cotgreave I.A., Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50 (Suppl. 1): 31–42.
(check this in PDF content)
7
Poole P., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; (2): CD001287.
(check this in PDF content)
8
Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22 (2): 209–221.
(check this in PDF content)
9
Decramer M., Rutten,van Molken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebocontrolled trial. Lancet 2005; 365 (9470): 1552–1560.
(check this in PDF content)
10
Antonelli,Incalzi R., Imperiale C., Bellia V. et al.Do GOLD stages of COPD severity really correspond to differences in health status? Eur. Respir. J. 2003; 22 (3): 444–449.
(check this in PDF content)
11
McFadden E.R. Jr., Linden D.A.A reduction in maximum midexpiratory flow rate. A spirographic manifestation of small airway disease. Am. J. Med. 1972; 52 (6): 725–737.
(check this in PDF content)
12
Gelb A.F., Zamel N.Simplified diagnosis of small-airway obstruction. N. Engl. J. Med. 1973; 288 (8): 395–398.
(check this in PDF content)
13
Goldman M.D., Saadeh C., Ross D.Clinical applications of forced oscillation to assess peripheral airway function. Respir. Physiol. Neurobiol. 2005; 148 (1–2): 179–194.
(check this in PDF content)
14
Grimby G., Takishima T., Graham W. et al.Frequency dependence of flow resistance in patients with obstructive lung disease. J. Clin. Invest. 1968; 47 (6): 1455–1465.
(check this in PDF content)
15
Evans T.M., Rundell K.W., Beck K.C. et al.Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. Chest 2005; 128 (4): 2412–2419.
(check this in PDF content)
16
US National Institutes of Health. The effect of high dose N-acetylcysteine on airtrapping and airway resistance of chronic obstructive pulmonary disease – a double-blinded, randomized, placebo-controlled trial. NCT01136239. Clinical Trials.gov. Bethesda, MD: National Institutes of Health; 2010. http://www.clinicaltrials.gov/ct2/show/mNCT01136239. Updated June 2, 2010.
(check this in PDF content)
17
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease website. http://www.gold, copd.org/uploads/users/fi les/GOLD_Report_2011_Feb21.pdf. Accessed December 7, 2012.
(check this in PDF content)
18
American Thoracic Society. Standardization of spirometry,
(check this in PDF content)
19
4 update. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 1107–1136. 19.Ip M.S., Ko F.W., Lau A.C. et al.; Hong Kong Thoracic Society; American College of Chest Physicians (Hong Kong and Macau Chapter). Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 2006; 129 (2): 384–392.
(check this in PDF content)
20
Oostveen E., MacLeod D., Lorino H. et al.ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur. Respir. J. 2003; 22 (6):1026–1041.
(check this in PDF content)
21
Crim C., Celli B., Edwards L.D. et al.ECLIPSE investigators. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir. Med. 2011; 105 (7): 1069–1078.
(check this in PDF content)
22
Macklem P.T., Mead J.Resistance of central and peripheral airways measured by a retrograde catheter. J. Appl. Physiol. 1967; 22 (3): 395–401.
(check this in PDF content)
23
Burgel P.R., Bourdin A., Chanez P. et al. Update on the roles of distal airways in COPD. Eur. Respir. Rev. 2011; 20 (119): 7–22.
(check this in PDF content)
24
Hogg J.C., Chu F., Utokaparch S. et al.The nature of smallairway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350 (26): 2645–2653.
(check this in PDF content)
25
Caramori G., Di Gregorio C., Carlstedt I. et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004; 45 (5): 477–484.
(check this in PDF content)
26
Rabe K.F., Hurd S., Anzueto A. et al.Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the Downloaded From: http://journal.publications.chestnet.org/ by a Zambon Group User on 07/02/2013.
(check this in PDF content)
27
Bourdin A., Burgel P.R., Chanez P. et al. Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. Eur. Respir. Rev. 2009; 18 (114): 198–212.
(check this in PDF content)
28
Calverley P.M., Koulouris N.G.Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur. Respir. J. 2005; 25 (1): 186–199.
(check this in PDF content)
29
King G.G., Downie S.R., Verbanck S. et al.Effects of methacholine on small airway function measured by forced oscilation technique and multiple breath nitrogen washout in normal subjects. Respir. Physiol. Neurobiol. 2005; 148 (1–2): 165–177.
(check this in PDF content)
30
Mahut B., Caumont,Prim A., Plantier L. et al.Relationships between respiratory and airway resistances and activityrelated dyspnea in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 165–171.
(check this in PDF content)
31
Brochard L., Pelle G., de Palmas J. et al. Density and frequency dependence of resistance in early airway obstruction. Am. Rev. Respir. Dis. 1987; 135 (3): 579–584.
(check this in PDF content)
32
Faria A.C., Costa A.A., Lopes A.J. et al.Forced oscillation technique in the detection of smoking-induced respiratory alterations: diagnostic accuracy and comparison with spirometry. Clinics (Sao Paulo) 2010; 65 (12): 1295–1304.
(check this in PDF content)
33
Black P.N., Morgan,Day A., McMillan T.E. et al. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease (ISRCTN21676344) (ISRCTN21676344). BMC Pulm. Med. 2004; 4: 13.
(check this in PDF content)
34
Poole P.J., Black P.N.Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 2001; 322 (7297): 1271–1274.
(check this in PDF content)
35
Benrahmoune M., Therond P., Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic. Biol. Med. 2000; 29 (8): 775–782.
(check this in PDF content)
36
Gressier B., Cabanis A., Lebegue S. et al.Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: comparison in vitro of some thiol-containing drugs. Meth. Find Exp. Clin. Pharmacol. 1994; 16 (1): 9–13. Применение высоких доз N-ацетилцистеина у пациентов со стабильным течением ХОБЛ
(check this in PDF content)
37
Kharazmi A., Nielsen H., Schiotz P.O.N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int. J. Immunopharmacol. 1988; 10 (1): 39–46.
(check this in PDF content)
38
Stolarek R., Bialasiewicz P., Nowak D. N-acetylcysteine effect on the luminol-dependent chemiluminescence pattern of reactive oxygen species generation by human polymor phonuclear leukocytes . Pulm. Pharmacol. Ther. 2002; 15 (4): 385–392.
(check this in PDF content)
39
Borgstrom L., Kagedal B.Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos. 1990; 11 (2): 131–136.
(check this in PDF content)
40
Bridgeman M.M., Marsden M., Selby C. et al.Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49 (7): 670–675.
(check this in PDF content)
41
Benedetto F., Aceto A., Dragani B. et al.Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm. Pharmacol. Ther. 2005; 18 (1): 41–47.
(check this in PDF content)
42
Kasielski M., Nowak D.Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir. Med. 2001; 95 (6): 448–456.
(check this in PDF content)
43
Demedts M., Behr J., Buhl R. et al.IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242.
(check this in PDF content)
44
Cotgreave I.A., Moldeus P. Lung protection by thiol-containing antioxidants. Bull. Eur. Physiopathol. Respir. 1987; 23 (4): 275–277.
(check this in PDF content)
45
Jeffery P.K., Rogers D.F., Ayers M.M. Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. Eur. J. Respir. Dis. Suppl. 1985; 139: 117–122.
(check this in PDF content)
46
Rubio M.L., Sanchez,Cifuentes M.V., Ortega M. et al. N-acetylcysteine prevents cigarette smoke induced small airways alterations in rats. Eur. Respir. J. 2000; 15 (3): 505–511.
(check this in PDF content)
47
Bridgeman M.M., Marsden M., MacNee W. et al.Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 1991; 46 (1): 39–42.
(check this in PDF content)
48
Stav D., Raz M.Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136 (2): 381–386.
(check this in PDF content)
49
Hanaoka M., Droma Y., Chen Y. et al. Carbocisteine protects against emphysema induced by cigarette smoke extract in rats. Chest 2011; 139 (5): 1101–1108.
(check this in PDF content)
50
Rubio M.L., Martin,Mosquero M.C., Ortega M. et al.Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004; 125 (4): 1500–1506.
(check this in PDF content)
51
Zheng J.P., Kang J., Huang S.G. et al.Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371 (9629): 2013–2018.
(check this in PDF content)
52
Niederman M.S., Rafferty T.D., Sasaki C.T. et al. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory trac. Am. Rev. Respir. Dis. 1983; 127 (1): 85–90.
(check this in PDF content)
53
Suer E., Sayrac S., Sarinay E. et al.Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J. Infect. Chemother. 2008; 14 (4): 333–336.
(check this in PDF content)
54
Gerrits C.M., Herings R.M., Leufkens H.G., Lammers J.W. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (5): 795–798. Поступила 12.08.13
(check this in PDF content)